💬In plain words
What the trial is, and whether it could suit you
Although both enteric-coated and plain formulations of aspirin are being used commonly, there are no high-quality comparisons between these formulations with respect to clinical efficacy outcomes in patients with atherosclerotic cardiovascular diseases (ASCVD). Air pollution is also a major contributor to the excess risk of cardiovascular events in many regions of the world. However, little is known about the effect of individual-level mitigation strategies against air pollution in reducing cardiovascular outcomes. The purpose of the first randomization is to compare the efficacy and safety of enteric-coated versus plain low-dose (81 mg) aspirin formulations in a double-blind fashion. The second randomization compares a multifaceted intervention including one-page educational flashcard, cell phone text messages alerting participants on polluted days, recommending them to stay indoors or
Sign in to get the eligibility rules as simple questions to take to your doctor.
📋 Eligibility rules (as published)
Inclusion Criteria:
* Adult patients (≥18 years) with documented ASCVD defined as at least one of the following:
* Coronary artery disease (CAD):
1. Previous or recent documented type I myocardial infarction \*(if not specified, will be assumed as type I)
2. History of coronary revascularization (percutaneous coronary intervention or coronary artery bypass graft surgery)
3. History of obstructive CAD (\>50% stenosis) documented by coronary computed tomography (CT) or conventional angiography
* Peripheral arterial disease (PAD):
1. Previous or recent acute ischemic limb event (\>7 days prior)
2. History of previous endovascular/surgical lower or upper extremities revascularization for an atherosclerotic cause
3. History of ulcer or lower extremities amputation due to ASCVD.
* Carotid arterial diseases:
1. History of previous endovascular/surgical carotid artery revascularization for atherosclerotic causes
2. History of \> 50% carotid artery stenosis based on documented imaging tests (Duplex US, CT angiography, magnetic resonance angiography, or conventional angiography)
* Ischemic stroke:
1. History of recent or previous documented ischemic stroke not due to atrial fibrillation, endocarditis, or systemic hypoperfusion/hypotension, being treated with low-dose aspirin
* Inhabitant of Tehran province
* Willing to participate and able to provide written informed consent
Exclusion Criteria:
* Being within 72 days of acute/unstable atherosclerotic cardiovascular events (acute myocardial infarction, acute limb event, and acute ischemic stroke), or within 72 hours of revascularization.
* Patients receiving triple antithrombotic therapy
* History of upper gastrointestinal bleeding within the past 30 days
* History of intracranial hemorrhage within the past 30 days
* End-stage kidney disease with estimated creatinine clearance \< 15 mL/min, or undergoing hemodialysis or peritoneal dialysis
* Known comorbidities associated with poor prognosis (e.g., metastatic cancer) in conjunction with an estimated life expectancy of less than one year according to the treating clinician
* Any other conditions that make the participants unsuitable for recruitment or follow-up (e.g., illiteracy)
* Not having aspirin as part of the planned durable treatment regimen
* Inability to receive/read text messages/phone calls by personal mobile phone (or that of a caregiver who lives with the patient and is willing to relay messages)
* The full list of exclusion criteria is provided in the study protocol
💊
What it tests
- Enteric-coated aspirin
- Plain aspirin
- Hybrid strategy
Rajaie Cardiovascular Medical and Research Center
Tehran, Iran
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
HealthTeky